EDIT in the 13F filings
Editas Medicine Inc · CUSIP 28106W103
- Quarter end
- 31 Mar 2024
- the date the book describes
- Filed
- 15 May 2024
- latest of these filings; the earliest 15 May 2024
- Managers listing it
- 2
- at least, of 95 tracked, among listed positions
- Comparable managers
- 93
- filed both Q4 2023 and Q1 2024; 1 listed it in both
- Shares listed
- 945,496
- combined, among listed positions
- Reported value
- $7.0m
- combined, at the quarter end
Among the 93 comparable managers: 1 buyer (opened or added shares) and 2 sellers (trimmed or exited), at least, among listed positions. Their net change in shares is not known from listed positions, because at least one of them lists it in only one of the two quarters.
Managers listing EDIT in Q1 2024
2 of 2 holders
| Action | Filing | |||||
|---|---|---|---|---|---|---|
| Woodline Partners LP | 895,000 | $6.6m | 0.06% | Trimmed | -401 | 15 May 2024 (the filing on sec.gov) |
| PDT Partners LLC | 50,496 | $375k | under 0.1% | New | new | 15 May 2024 (the filing on sec.gov) |
Largest increases and reductions, by shares
Increases
- PDT Partners LLCnew position · 50,496 shares now+50,496
Reductions
- Woodline Partners LPexisting position · 895,000 shares now-401
New positions and exits
New (1)
- PDT Partners LLC$375k
Exited (1)
- Caxton Associates LLPwas $330k
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q1 2016 | 3 | $84m | n.a. | n.a. |
| Q2 2016 | 3 | $49m | n.a. | n.a. |
| Q3 2016 | 3 | $27m | n.a. | n.a. |
| Q4 2016 | 2 | $33m | n.a. | n.a. |
| Q1 2017 | 4 | $85m | n.a. | n.a. |
| Q2 2017 | 4 | $69m | n.a. | n.a. |
| Q3 2017 | 5 | $103m | n.a. | n.a. |
| Q4 2017 | 5 | $159m | n.a. | n.a. |
| Q1 2018 | 7 | $180m | n.a. | n.a. |
| Q2 2018 | 5 | $199m | n.a. | n.a. |
| Q3 2018 | 5 | $190m | n.a. | n.a. |
| Q4 2018 | 4 | $136m | n.a. | n.a. |
| Q1 2019 | 4 | $182m | n.a. | n.a. |
| Q2 2019 | 4 | $189m | n.a. | n.a. |
| Q3 2019 | 4 | $171m | n.a. | n.a. |
| Q4 2019 | 6 | $266m | n.a. | n.a. |
| Q1 2020 | 7 | $172m | n.a. | n.a. |
| Q2 2020 | 7 | $361m | n.a. | n.a. |
| Q3 2020 | 5 | $378m | n.a. | n.a. |
| Q4 2020 | 6 | $969m | n.a. | n.a. |
| Q1 2021 | 7 | $498m | n.a. | n.a. |
| Q2 2021 | 6 | $540m | n.a. | n.a. |
| Q3 2021 | 5 | $349m | n.a. | n.a. |
| Q4 2021 | 5 | $178m | n.a. | n.a. |
| Q1 2022 | 6 | $86m | n.a. | n.a. |
| Q2 2022 | 6 | $41m | n.a. | n.a. |
| Q3 2022 | 5 | $42m | n.a. | n.a. |
| Q4 2022 | 5 | $29m | n.a. | n.a. |
| Q1 2023 | 3 | $20m | n.a. | n.a. |
| Q2 2023 | 4 | $47m | n.a. | n.a. |
| Q3 2023 | 4 | $44m | n.a. | n.a. |
| Q4 2023 | 3 | $21m | 1 | 2 |
| Q1 2024 | 2 | $7.0m | 1 | 2 |
| Q2 2024 | 3 | $6.3m | 3 | 0 |
| Q3 2024 | 2 | $3.5m | 0 | 2 |
| Q2 2026 | 1 | $12m | 14 | 9 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
EDIT and GILD →EDIT and AMGN →EDIT and ARGX →Choose a stock to compare with EDIT →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own EDIT, latest filings →Back to the 13F Explorer →